


Serial No.: 09/875,264
Applicant: NAIR et al
Title: METHODS FOR TREATING
CANCERS AND PATHOGEN.

Atty: MJW
Date: 2-20-2002
Client: DUKE UNIV.
Ref: 1579-579

____ Amendment
____ Pages Specification
____ Claims
____ Sheets Drawings: Formal _____
Informal _____
____ Declaration (____ Pages)
____ Assignment
____ Priority Document
____ Base Issue Fee Transmittal
____ Fee (Check)



Other: IDS + PTD - 1449 FORMS + REFS.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

NAIR et al

Atty. Ref.: 1579-579

Serial No.: 09/875,264

Group Art Unit:

Filed: June 7, 2001

Examiner:

For: METHODS FOR TREATING CANCERS AND PATHOGEN INFECTIONS
USING ANTIGEN-PRESENTING CELLS LOADED WITH RNA

* * * * *

February 20, 2002

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of Patents
and Trademarks
Washington, DC 20231

Sir:

Attached is Form PTO-1449 listing the enclosed documents.

This IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to comply fully.

Contingent Request Under Rule 97(c): Should a first action on the merits have been issued on the same day or before this IDS is filed, please accept this IDS under Rule 97(c) and charge the requisite Rule 17(p) fee to our

NAIR et al -- Serial No.: 09/875,264

Deposit Account No. 14-1140 (1579-579) and proceed to consider this IDS.

Consideration of the foregoing and enclosures plus the return of a copy of the herewith Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 are earnestly solicited.

Respectfully submitted,

NIXON & VANDERHYE, P.C.

By Mary J. Wilson
Mary J. Wilson
Reg. No. 82,955

MJW:tat

1100 North Glebe Road
8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE
CITATION

ATTY. DOCKET NO.

SERIAL NO.

1579-579

09/875,264

APPLICANT


NAIR et al

FILING DATE

GROUP

June 7, 2001

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,306,388	10/2001	Nair et al			
	5,827,642	10/1998	Riddell et al			
	4,918,164	4/1990	Hellstrom et al			
	5,662,907	9/1997	Kubo et al			
	6,130,087	10/2000	Srivastava et al			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Rouse et al, "Induction In Vitro of Primary Cytotoxic T-Lymphocyte Responses with DNA Encoding Herpes Simplex Virus Proteins", Journal of Virology 68(9):5685-5689 (1994)
	Riddell et al, "Class 1 MHC-Restricted Cytotoxic T Lymphocyte Recognition of Cells Infected With Human Cytomegalovirus Does Not Require Endogenous Viral Gene Expression", The Journal of Immunology 146(8):2795-2804 (1991)
	Boczkowski et al, "Dendritic Cells Pulsed with RNA are Potent Antigen-Presenting Cells In Vitro and In Vivo", J. Exp. Med. 284:465-472 (1996)
	Rabinovich et al, "Vaccine Technologies: View to the Future", Science 265:1401-1404 (1994)
	Morel et al, "Does preventive vaccination with engineered tumor cells work in cancer-prone transgenic mice?", Cancer Gene Therapy 5(2):92-100 (1998)
	Gomez-Navarro et al, "Gene Therapy for Cancer", European Journal of Cancer 35(6):867-885 (1999)
	Sprent et al, "Lymphocyte Life-Span and Memory", Science 265:1395-1399 (1994)
	Oldstone et al, "How Viruses Escape from Cytotoxic T Lymphocytes: Molecular Parameters and Players", Virology 234:179-185 (1997) Article No. VY978674
	Pardoll, "Cancer Vaccines", Nature Medicine Vaccine Supplement 4(5):525-531 (1998)
	Cohen et al, "Bumps on the Vaccine Road", Science 265:1371 (1994)
	Gura, "Cancer Models", Systems for Identifying New Drugs Are Often Faulty, Science 278:1041-1042 (1997)

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

1579-579

09/875,264

APPLICANT

NAIR et al

(Use several sheets if necessary)

FILING DATE

GROUP

June 7, 2001

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,831,068	11/1998	Nair et al			
	5,853,719	12/1998	Nair et al			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
WO 94/04171	3/1994	PCT			
WO 94/04557	3/1994	PCT			
WO 97/41210	11/1997	PCT			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Crusinberry et al, "Immunotherapy of Renal Cell Cancer", Seminars in Surgical Oncology 7:221-229 (1991)
	Rosenberg et al, "Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients With Metastatic Melanoma", The New England Journal of Medicine 319(25):1676-1680 (1998)
	Donis-Keller, H., "Site specific enzymatic cleavage of RNA", Nucleic Acids Research 7(1):179-192 (1979)
	Friedman, H., "Discussion Paper: Protective Immunity in Leukemic Mice Treated with Specific "Immunogenic" RNA", Annals New York Academy of Sciences 277(00):708-715 (1976)
	Greenup et al, "Anti-Tumor Cytotoxicity of Poly(A)-Containing Messenger RNA Isolated From Tumour-Specific Immunogenic RNA", Br. J. Cancer 38:55-63 (1978)
	Aarons et al, "Immune RNA Therapy as an Effective Adjuvant Immunotherapy After Surgery: An Animal Model", Journal of Surgical Oncology 23:21-26 (1983)
	Porgador et al, "Combined Vaccination with Major Histocompatibility Class I and Interleukin 2 Gene-transduced Melanoma Cells Synergizes the Cure of Postsurgical Established Lung Metastases", Cancer Research 55:4941-4949 (1995)
	Röttschke et al, "Exact prediction of a natural T cell epitope", Eur. J. Immunol. 21:2891-2894 (1991)
	van den Bosch et al, "T-Cell-Independent Macrophase Activation in Mice Induced with rRNA from <i>Listeria monocytogenes</i> and Dimethyldioctadecylammonium Bromide", Infection and Immunity 53(3):611-615 (1986)
	Boon et al, "Human Tumor Antigens Recognized by T Lymphocytes", J. Exp. Med. 183:725-729 (1996)
	Rifkind et al, "Delayed Hypersensitivity to Fungal Antigens in Mice. II. Molecular Classes in Immunogenic RNA Extracts that Transfer Delayed Hypersensitivity", The Journal of Infectious Diseases 133(5):523-532 (1976)
	Rifkind et al, "Delayed Hypersensitivity to Fungal Antigens in Mice. III. Characterization of the Active Component in Immunogenic RNA Extracts", The Journal of Infectious Diseases 133(5):533-537 (1976)
	Nair et al, "Cells Treated with TAP-2 Antisense Oligonucleotides Are Potent Antigen-Presenting Cells In Vitro and In Vivo", The Journal of Immunology 156:1772-1780 (1996)
	Inada et al, "Comparison of the Ability of Lactate Dehydrogenase-Elevating Virus and Its Virion RNA To Infect Murine Leukemia Virus-Infected or -Uninfected Cell Lines", Journal of Virology 67(9):5698-5703 (1993)
	Duke et al, "In Vitro Induction of Antibody Formation With Immunogenic RNA", Annals New York Academy of Sciences 207:145-159 (1973)
	Garvey et al, "Characterization of RNA-Antigen Complexes", Annals New York Academy of Sciences 207:258-278 (1973)
	Dodd et al, "Immunogenic RNA in the Immunotherapy of Cancer: The Transfer of Antitumor Cytotoxic Activity and Tuberculin Sensitivity to Human Lymphocytes Using Xenogeneic Ribonucleic Acid", Annals New York Academy of Sciences 207:454-467 (1973)
	Walker et al, "Cationic lipids direct a viral glycoprotein into the class I major histocompatibility complex antigen-presentation pathway", Proc. Natl. Acad. Sci. USA 89:7915-7918 (1992)

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO.	SERIAL NO.
	1579-579	09/875,264
	APPLICANT	
	NAIR et al	
	FILING DATE	GROUP
	June 7, 2001	

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Vyas et al, "Specific Immunotherapy Proposed for Hepatitis B Virus Infection", Develop. biol. Standard. 30:350-356 (1975)		
	Wu et al, "Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens", Proc. Natl. Acad. Sci. USA 92:11671-11675 (1995)		
	Lin et al, "Treatment of Established Tumors with a Novel Vaccine That Enhances Major Histocompatibility Class II Presentation of Tumor Antigen", Cancer Research 56:21-26 (1996)		
	Machado et al, "Dialyzable transfer factor in experimental Chagas' disease: in vitro studies", Trop. Med. Parasit. 37:399-402 (1986)		
	Slomsky et al, "Induction of Antibody Synthesis In Vitro By Immunogenic RNA", Annals Med. Sect. Pol. Acad. Sci. 20(4):255-268 (1975)		
	KIM, et al. Interleukin-secreting Mouse Fibroblasts Transfected with Genomic DNA from Murine Melanoma Cells Prolong the Survival of Mice with Melanoma. Cancer Research. 15 May 1994, Vol 54, pages 2531-2535		
	BHOOPALAM et al. Surface Immunoglobulins of Circulating Lymphocytes in Mouse Plasmacytoma. II. The Influence of Plasmacytoma RNA on Surface Immunoglobulins of Lymphocytes. Blood. April 1972, Vol. 39, No. 4, pages 465-471		
	VILLARREAL, L.P. et al. Common Mechanisms of Transformation by Small DNA Tumor Viruses. Washington, D. C.: American Society of Microbiology. 1989, Chapter 1, pages 1-17		
*Examiner		Date Considered	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.